14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 78.004 Session: HIV: Opportunistic Infections & Malignancies Date: Friday, March 12, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria S. Isa 1 , L. N. Gwamzhi 2 , C. Akolo 3 , C. Ukoli 4 1 Federal Staff Hospital, Garki II, Abuja, Nigeria, 2 Grenada General Hospital, St Georges, St George's, Grenada, 3 SRA International Inc, Rockville, MD, USA, 4 Jos University Teaching Hospital, Jos, Plateau, Nigeria Background: In the era of highly active antiretroviral therapy (HAART), hepatitis B and C virus (HBV and HCV) co-infection have emerged as significant co-morbid conditions. Local reports indicate that co-infection is not uncommon in Nigeria as in other sub-Saharan African countries. Whether treatment outcomes of HIV mono-infected patients differ from those with co-infection remains largely unknown. We hypothesised that co-infected patients will have lower CD4+ count recovery and viral load reduction following HAART. Methods: A cohort study in antiretroviral therapy-naïve HIV-infected adults involving 150 cases (HIV and hepatitis co-infection) and 150 controls (HIV infection only). Patients’ care was according to the National guidelines and patients received first line therapy mostly comprising Lamivudine, Stavudine and Nevirapine. Additionally, abdominal ultrasound and prothrombin time tests were done when necessary. Medication adherence was monitored using pharmacy log system, and CD4+ cell counts and HIV viral load (VL) were compared at baseline, 3 and 6 months of therapy. Results: There were 98(65.3%) and 96(64%) female cases and controls (p=0.79) respectively . The mean ages of cases and controls were 38±8.4 and 37±8.9 years (p=0.20) respectively. Cases comprised 73(48%) HBV, 70(47%) HCV and 7(5%) with HBV plus HCV infection. Medication adherence was >95% in both arms. Attrition rate was 2.7%(8); seven of these were co-infected. Five cases (3.3%) compared to zero controls developed clinical hepatitis. The proportions of patients with CD4+ count
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 78.005 Session: HIV: Opportunistic Infections & Malignancies Date: Friday, March 12, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Pulmonary microbiology of HIV positive subjects with community-acquired pneumonia (CAP) with special emphasis on Mycoplasma pneumoniae U. RAO 1 , E. Shankar 2 , N. Kumarasamy 3 , P. Balakrishnan 3 , S. Solomon 3 1 Raga's Dental College, 600119, India, 2 University of Madras, Chennai, India, 3 YRG CARE, Chennai, India Background: A great deal of effort has been devoted to understanding the role of AIDSassociated mycoplasmas in recent years. However, the role of Mycoplasma pneumoniae in HIV disease remains unclear. Methods: We studied 300 adult HIV infected persons (200 with community-acquired pneumonia (CAP) and 100 with no respiratory illness) and 75 HIV uninfected persons with CAP and analysed the prevalence of respiratory pathogens. Results: Prevalence of M. pneumoniae was 17% by induced sputum and 11.3% by throat swab culture in HIV positive subjects. Seroprevalence of anti-M. pneumoniae IgM was 11.7% by ELISA and 14.3% by gelatin microparticle agglutination test. Prevalence of M. pneumoniae among HIV negative cases was relatively low. Streptococcus pneumoniaewas predominant (28%) among subjects with lower respiratory disease, whereas Staphylococcus aureus (15%) was more common among cases with upper respiratory illness. Rales (P=0.001), pharyngeal erythema (P=0.02), cervical adenopathy (P=0.004) and crepitations (P=0.001) showed significance in relation to M. pneumoniae positivity. Statistical significance was observed with regard to total lymphocyte count (P=0.02) and erythrocyte sedimentation rate (P=0.04), and M. pneumoniae positivity. Conclusion: The prevalence of M. pneumoniae in HIV infected subjects was relatively higher than HIV uninfected subjects with respiratory disease.
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96: When citing these abstracts please
Page 145: When citing these abstracts please
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

Create successful ePaper yourself

Delete template?

Save as template?